Category: 20327-23-5

20327-23-5, 1-Cyclopropylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a stirred solution of 51f (50 mg, 1 eq) in DMSO (0.5 mL), is added 1-cyclopropylpiperazine (38 mg, 2 eq), Et3N (19 muL, 1.1 eq) and heated at 50 C. during 2 h. Ammonium acetate (500 mg) is added and the solution is heated at 140 C. during 1 h. The solution is diluted with H2O/AcOH and purified by prep HPLC to give 5008 (8 mg, 13%)., 20327-23-5

20327-23-5 1-Cyclopropylpiperazine 4742004, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; US2010/261714; (2010); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

20327-23-5, 1-Cyclopropylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of N-(l-(lH-indol-3-yl)hexan-2-yl)-2-bromothiazole-5- carboxamide (0.20 g, 0.49 mmol) and 1-cyclopropylpiperazine (0.07 g, 0.54 mmol) in CH3CN (4.5 mL) was added K2CO3 (0.20 g, 1.47 mmol) and the reaction mixture was heated at 80 C for 16 h. The reaction mixture was concentrated in vacuo. The residue was diluted with H20 (10 mL) and extracted with 10% MeOH in DCM (10 mL). The organic layer was separated, dried over anhydrous Na2S04 and concentrated in vacuo. The crude obtained was purified by column chromatography (silica 230-400 mesh, 0 to 10% MeOH in DCM) and then triturating with petroleum ether (6 mL), pentane (10 mL) and DCM (2 mL) to afford N-(l-(lH-indol-3- yl)hexan-2-yl)-2-(4-cyclopropylpiperazin-l-yl)thiazole-5-carboxamide (0.14 g, 63%) as an off- white solid. HPLC Purity: 99.0%. LC/MS (ESI) m/e [M+H]+/RT (min)/%: (0271) 452.00/2.91/98.8%. 1H NMR (400 MHz, DMSO- 6) delta 0.35-0.44 (m, 4H), 0.82 (t, = 6.9 Hz, 3H), 1.16-1.37 (m, 4H), 1.40-1.60 (m, 2H), 1.62-1.68 (m, 1H), 2.60-2.68 (m, 4H), 2.73-2.98 (m, 2H), 3.40-3.48 (m, 4H), 4.04-4.18 (m, 1H), 6.92-6.99 (m, 1H), 7.04 (t, = 7.6 Hz, 1H), 7.09 (s, 1H), 7.31 (d, = 8.3 Hz, 1H), 7.57 (d, = 7.8 Hz, 1H), 7.80 (s, 1H), 7.94 (d, = 8.8 Hz, 1H), 10.75 (brs, 1H).

20327-23-5, 20327-23-5 1-Cyclopropylpiperazine 4742004, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; NEUROPORE THERAPIES, INC.; WRASIDLO, Wolfgang; STOCKING, Emily, M.; HALL, Adrian; MACCOSS, Malcolm; (139 pag.)WO2017/20010; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

4-Cyclopropylmethyl-piperazine-1-carboxylic Acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl Ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-cyclopropylpiperazine, yield 62%. Recrystallisation from 0.2 M HCl gave white crystals, m.p. 238-239 C.; 1H NMR (DMSO-d6): delta 11.51 (br s, 1H), 8.61-8.55 (m, 1H), 8.30-8.20 (m, dd, 1H), 7.32-7.19 (m, d+s, 5H), 4.44-4.00 (br, 2H), 3.80-3.40 (br m, 4H), 3.29-2.93 (br m, 4H), 1.28-1.05 (br m, 1H), 0.75-0.58 (m, 2H), 0.50-0.35 (m, 2H).IR (KBr): nu 1730, 1713 (C=O) cm-1.

20327-23-5, The synthetic route of 20327-23-5 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; Ebdrup, Soren; de Jong, Johannes Cornelis; Jacobsen, Poul; Hansen, Holger Claus; Vedso, Per; US2003/166644; (2003); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

20327-23-5, 1-Cyclopropylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

0.1 ml diisopropylethylamine, 64.2 mg (0.20 mmol) TBTU and 27.0 mg (0.20 mmol) HOBt was added to a mixture of 100 mg (0.20 mmol) (R)-3-(4-amino-3-chloro-5-methyl-phenyl)-2-{[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carbonyl]-amino}-propionic acid, 10 ml THF and 1 ml DMF, the mixture was stirred for 15 hours at ambient temperature and then combined with 80 mg (0.60 mmol) 1-cyclopropyl-piperazine. The reaction mixture was stirred for 3 hours at ambient temperature, combined with 20 ml semisaturated sodium hydrogen carbonate solution and extracted twice with 20 ml of ethyl acetate. The combined organic phases were washed once with 20 ml saturated saline solution, dried over sodium sulphate and evaporated down under reduced pressure. The residue was purified by column chromatography through silica gel. Yield: 89.5 mg (74% of theory) ESI-MS: (M+H)+=608/610 (Cl), 20327-23-5

As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference：
Patent; Boehringer Ingelheim International GmbH; US2005/282857; (2005); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

Example 277 Synthesis of 3-[1-{4-[2-(4-Cyclopropyl-piperazin-1-yl)-2-oxo-ethyl]-3,5-dimethyl-1H-pyrrol-2-yl }-meth-(Z)-ylidene]-5-(2,6-dichloro-phenylmethanesulfonyl)-1,3-dihydro-indol-2-one A mixture of {5-[5-(2,6-dichloro-phenylmethanesulfonyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-acetic acid (208 mg, 0.4 mmol), HOBt (54 mg, 1 eq.) and EDAC (153 mg, 2 eq.) in DMF (1.5 mL) was stirred at rt for 30 mins. To the mixture was added 1-cyclopropyl-piperazine (101 mg, 2 eq.) in DMF (1.5 mL). After stirring at rt for overnight, the precipitate was collected by vacuum filtration, washed with water, sodium bicarbonate and ether to give 108 mg (43%) of the titled compound. 1H-NMR (400 MHz, DMSO-d6) delta 13.46 (s, 1H, NH), 11.26 (s, 1H, NH), 8.17 (d, 1H), 7.76 (s, 1H), 7.48 (d, 1H), 7.46 (s, 1H), 7.36 (m, 2H), 6.99 (d, J=8 Hz, 1H), 4.84 (s, 2H), 3.49 (s, 2H), 3.46 (m, 2H), 3.39 (m, 2H), 2.47 (m, 4H), 2.25 (s, 3H, CH3), 2.22 (s, 3H, CH3), 1.6 (m, 1H), 0.4 (m, 2H), 0.31 (m, 2H). MS m/z 625 [M-1]., 20327-23-5

As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference：
Patent; SUGEN, INC.; US2003/125370; (2003); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

100mL round-bottom flask was added 1.84g (10mmol) compound II, 1.26g (10mmol) and Compound III-2 dry 20mL of THF, the resulting mixture was stirred at ice-water bath, was added 2.48 g (12mmol) DCC, the stirring was continued at room temperature overnight. TLC showed the reaction was complete. document.write(“”); The reaction mixture was poured into ice water, stirred, and extracted with dichloromethane 50mL × 3, the combined organic extracts were washed with saturated brine, dried over anhydrous sodium sulfate, the solvent was distilled off on a rotary evaporator and the residue obtained was column chromatography to afford the product I-2, as a white solid.

20327-23-5, As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference：
Patent; Zhejiang Pharmaceutical College; Guo, Zhanghua; (6 pag.)CN104387341; (2016); B;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

100mL round-bottom flask was added 1.84g (10mmol) compound II, 1.26g (10mmol) and Compound III-2 dry 20mL of THF, the resulting mixture was stirred at ice-water bath, was added 2.48 g (12mmol) DCC, the stirring was continued at room temperature overnight. TLC showed the reaction was complete. document.write(“”); The reaction mixture was poured into ice water, stirred, and extracted with dichloromethane 50mL × 3, the combined organic extracts were washed with saturated brine, dried over anhydrous sodium sulfate, the solvent was distilled off on a rotary evaporator and the residue obtained was column chromatography to afford the product I-2, as a white solid.

20327-23-5, As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference：
Patent; Zhejiang Pharmaceutical College; Guo, Zhanghua; (6 pag.)CN104387341; (2016); B;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

20327-23-5, 1-Cyclopropylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

3 -Bromo-5 -nitro-toluene, (7.7 8g, 36.0 mmol) and 1 -cyclopropylpiperazine (5 .0g, 39.6 mmol) were dissolved in 100 mL of dry t-BuOH and purged with N2 for 10 minutes. During the purge added t-BuXphos Palladacycle (620mg, 0.9Ommol) followed by sodium t-butoxide, (5.20g, 54.0 mmol) and reaction was allowed to stir at 30C under N2 for two hours. Solvent was removed under reduced pressure and the residue partitioned between EtOAc and water, then the organic phase washed with brine, dried (Na2504) and solvent removed under reduced pressure. The crude material was Isco purified on 5i02 with DCM changing to isocratic 10%/EtOAc/DCM as eluent to afford 6.75 g (64%) of JW-8a as a dark yellow, waxy solid. ?H NMR (400 MHz, Acetone-d6) oe 7.51 (t, J = 2.1 Hz, 1H), 7.43 (d, J = 0.6 Hz, 1H), 7.21 (s, 1H), 3.35 – 3.18 (m, 4H), 2.83 – 2.67 (m, 4H), 2.40 (s, 3H), 1.75 – 1.59 (m, 1H), 0.57 – 0.41 (m, 2H),0.38 (dt, J = 3.8, 2.5 Hz, 2H) ppm. ESI-MS m/z calc. 261.14774, found 262.0 (M+1)+; Retention time: 0.58 minutes., 20327-23-5

As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference£º
Patent; VERTEX PHARMACEUTICALS INCORPORATED; DAVIES, Robert, J.; CAO, Jingrong; COCKERILL, Meghan, Elise; COLLIER, Philip, Noel; DENINNO, Michael, Paul; DOYLE, Elisabeth; FRANTZ, James, Daniel; GAO, Huai; GOLDMAN, Brian, Anthony; GREY, Ronald, Lee; GRILLOT, Anne-laure; GU, Wenxin; HENDERSON, James, A.; IRARRAZAVAL, Raul Eduardo, Krauss; KOLPAK, Adrianne, Lynn; LIAO, Yusheng; MAGAVI, Sanjay Shivayogi; MALTAIS, Francois; MESSERSMITH, David; PIERCE, Albert, Charles; PEROLA, Emanuele; RYU, Elizabeth Jin-Sun; SYKEN, Joshua; WANG, Jian; (706 pag.)WO2016/197009; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

Step A:6-Bromo-2-(4-cyclopropylpiperazin-1-yl)benzothiazole; To a solution of 6-bromo-2-chlorobenzothiazole (8.2 g, 33 mmol) in EtOH (115 mL) was added Et3N (16.7 g, 165 mmol), followed by 1-cyclopropylpiperazine (5 g, 39.6 mmol). The mixture was heated at reflux for 12 h. Then the mixture was evaporated to remove EtOH. Water (120 mL) was added to the residue and the mixture was extracted with CH2CI2 (3 x 50 mL). The combined organic extracts were washed with brine, dried (Na2SO4) and concentrated to give a residue, which was purified by column chromatography on silica gel eluting with a mixture of EtOAc/petroleum ether (1 :10 with 0.1 % NH4OH added) to give 3.46 g (31 %) 6-bromo-2-(4-cyclopropylpiperazin-1-yl)benzothiazole.1H NMR (300 MHz, CDCI3): delta 7.70 (t, 1 H), 7.38 (dd, 2 H), 3.60 (d, 4 H), 2.80 (d, 4 H), 1.68 (d, 1 H), 0.50-0.39 (m, 4 H).

20327-23-5, As the paragraph descriping shows that 20327-23-5 is playing an increasingly important role.

Reference£º
Patent; NOVO NORDISK A/S; WO2007/110364; (2007); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

The 100 mg compound II, 75 mg compound III by adding 5 ml dichloromethane (DCM) in, stirring, 40 C reaction 2 hours, TLC monitoring, after the reaction, the solvent turns on lathe does, the reactant putting into the 100 ml water, ethyl acetate (20 ml ¡Á 3) extraction, standing liquid, organic phase are respectively 5% of NaHCO3 (20 Ml ¡Á 3), saturated salt water (20 ml ¡Á 3) washing, then drying water-free magnesium sulfate, filtered, reduced pressure to remove the ethyl acetate to get the yellow oily compound IV 83 mg.

20327-23-5, The synthetic route of 20327-23-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Southern Medical University; Chen Jianjun; Cheng Binbin; (22 pag.)CN109456284; (2019); A;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics